Francesmary Modugno

List of Publications by Year in Descending Order

105 papers	3,744 citations	32 h-index	58 g-index
112 ext. papers	4,515 ext. citations	6.5 avg, IF	4.21 L-index

#	Paper	IF	Citations
105	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 217-228	4	7
104	Validated biomarker assays confirm ARID1A loss is confounded with MMR deficiency, CD8 TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.. *Journal of Pathology*, **2021**,	9.4	3
103	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2021**,	5.1	2
102	DNA Methylation Profiles of Ovarian Clear Cell Carcinoma. *Cancer Epidemiology Biomarkers and Prevention*, **2021**,	4	2
101	Identification of a Locus Near Associated With Progression-Free Survival in Ovarian Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 1669-1680	4	2
100	Circulating CD14 HLA-DR monocytic cells as a biomarker for epithelial ovarian cancer progression. *American Journal of Reproductive Immunology*, **2021**, 85, e13343	3.8	1
99	Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 927-935	4	2
98	Gestational weight gain and risk of epithelial ovarian cancer. *Cancer Causes and Control*, **2021**, 32, 537-545	2.8	1
97	Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer. *Science Translational Medicine*, **2021**, 13, eabf8495	17.5	1
96	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. *British Journal of Cancer*, **2020**, 123, 793-802	8.7	16
95	Association Between Breastfeeding and Ovarian Cancer Risk. *JAMA Oncology*, **2020**, 6, e200421	13.4	24
94	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. *Gynecologic Oncology*, **2020**, 158, 702-709	4.9	5
93	The Association of Modifiable Breast Cancer Risk Factors and Somatic Genomic Alterations in Breast Tumors: The Cancer Genome Atlas Network. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 599-605	4	4
92	Identification of novel epithelial ovarian cancer loci in women of African ancestry. *International Journal of Cancer*, **2020**, 146, 2987-2998	7.5	8
91	Gender of offspring and risk of ovarian cancer: The HOPE study. *Cancer Epidemiology*, **2020**, 64, 101646	2.8	2
90	Offspring sex and risk of epithelial ovarian cancer: a multinational pooled analysis of 12 case-control studies. *European Journal of Epidemiology*, **2020**, 35, 1025-1042	12.1	2
89	Breastfeeding factors and risk of epithelial ovarian cancer. *Gynecologic Oncology*, **2019**, 153, 116-122	4.9	16

88	Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study. *International Journal of Epidemiology*, **2019**, 48, 822-830	7.8	13
87	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. *Modern Pathology*, **2019**, 32, 1834-1846	9.8	21
86	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. *Cancer Medicine*, **2019**, 8, 2503-2513	4.8	4
85	Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. *Cancer Causes and Control*, **2019**, 30, 537-547	2.8	9
84	Molecular mechanisms linking high body mass index to breast cancer etiology in post-menopausal breast tumor and tumor-adjacent tissues. *Breast Cancer Research and Treatment*, **2019**, 173, 667-677	4.4	16
83	A comprehensive gene-environment interaction analysis in Ovarian Cancer using genome-wide significant common variants. *International Journal of Cancer*, **2019**, 144, 2192-2205	7.5	11
82	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. *Mayo Clinic Proceedings*, **2018**, 93, 307-320	6.4	14
81	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. *British Journal of Cancer*, **2018**, 118, 1123-1129	8.7	10
80	Anthropometric characteristics and ovarian cancer risk and survival. *Cancer Causes and Control*, **2018**, 29, 201-212	2.8	3
79	Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. *International Journal of Epidemiology*, **2018**, 47, 460-472	7.8	16
78	Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. *American Journal of Epidemiology*, **2018**, 187, 366-377	3.8	7
77	Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium. *International Journal of Cancer*, **2018**, 142, 460-469	7.5	3
76	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. *Journal of Pathology: Clinical Research*, **2018**, 4, 250-261	5.3	38
75	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. *PLoS ONE*, **2018**, 13, e0197561	3.7	9
74	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	3
73	Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2018**, 27, 174-182	4	10
72	Somatic hematopoietic TP53 mosaicism in women with breast cancer exposed to ionizing radiation. *Breast Journal*, **2018**, 24, 852-854	1.2	
71	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. *British Journal of Cancer*, **2017**, 116, 524-535	8.7	18

70	Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. *International Journal of Cancer*, **2017**, 140, 2422-2435	7.5	18
69	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190
68	Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. *British Journal of Cancer*, **2017**, 116, 1223-1228	8.7	11
67	History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. *Cancer Causes and Control*, **2017**, 28, 469-486	2.8	19
66	Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies. *American Journal of Epidemiology*, **2017**, 185, 8-20	3.8	44
65	Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. *JAMA Oncology*, **2017**, 3, e173290	13.4	152
64	Alcohol consumption and breast tumor gene expression. *Breast Cancer Research*, **2017**, 19, 108	8.3	18
63	History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. *British Journal of Cancer*, **2017**, 117, 1063-1069	8.7	11
62	History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 1470-1473	4	8
61	The Association of Peripheral Blood Regulatory T-Cell Concentrations With Epithelial Ovarian Cancer: A Brief Report. *International Journal of Gynecological Cancer*, **2017**, 27, 11-16	3.5	5
60	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 420-424	4	3
59	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, **2016**, 141, 386-401	4.9	15
58	A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer. *International Journal of Cancer*, **2016**, 139, 2646-2654	7.5	6
57	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. *Cancer Discovery*, **2016**, 6, 1052-67	24.4	104
56	Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. *British Journal of Cancer*, **2016**, 115, 95-101	8.7	28
55	Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 780-90	4	8
54	The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. *Cancer Epidemiology*, **2016**, 41, 71-9	2.8	17
53	Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 446-54	4	6

52	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. *Oncotarget*, **2016**, 7, 69097-69110	3.3	4
51	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. *Oncotarget*, **2016**, 7, 72381-72394	3.3	11
50	A targeted genetic association study of epithelial ovarian cancer susceptibility. *Oncotarget*, **2016**, 7, 7381-9	3.3	7
49	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. *International Journal of Epidemiology*, **2016**, 45, 884-95	7.8	45
48	Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. *Obstetrics and Gynecology*, **2016**, 127, 828-836	4.9	24
47	PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. *Journal of Medical Genetics*, **2016**, 53, 800-811	5.8	121
46	Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 1114-24	4	27
45	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. *Human Genetics*, **2016**, 135, 741-56	6.3	18
44	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nature Genetics*, **2015**, 47, 164-71	36.3	177
43	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 1574-84	4	24
42	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. *Clinical Cancer Research*, **2015**, 21, 5264-76	12.9	24
41	Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. *Gynecologic Oncology*, **2015**, 136, 542-8	4.9	12
40	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. *Nature Communications*, **2015**, 6, 8234	17.4	40
39	Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. *Carcinogenesis*, **2015**, 36, 1341-53	4.6	20
38	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. *Human Molecular Genetics*, **2015**, 24, 5955-64	5.6	48
37	The molecular landscape of premenopausal breast cancer. *Breast Cancer Research*, **2015**, 17, 104	8.3	38
36	Population distribution of lifetime risk of ovarian cancer in the United States. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 671-676	4	67
35	Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. *Genetic Epidemiology*, **2015**, 39, 689-97	2.6	18

34	Use of common analgesics is not associated with ovarian cancer survival. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 1291-4	4	7
33	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. *PLoS ONE*, **2015**, 10, e0128106	3.7	15
32	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. *Human Molecular Genetics*, **2015**, 24, 3595-607	5.6	32
31	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). *Journal of Genetics and Genome Research*, **2015**, 2,		22
30	Prognosis and conditional disease-free survival among patients with ovarian cancer. *Journal of Clinical Oncology*, **2014**, 32, 4102-12	2.2	48
29	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. *Nature Genetics*, **2013**, 45, 362-70, 370e1-2	36.3	267
28	Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. *Cancer Causes and Control*, **2013**, 24, 989-1004	2.8	69
27	Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2013**, 22, 1677-86	4	53
26	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. *Nature Communications*, **2013**, 4, 1628	17.4	124
25	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. *Nature Communications*, **2013**, 4, 1627	17.4	85
24	Hormone response in ovarian cancer: time to reconsider as a clinical target?. *Endocrine-Related Cancer*, **2012**, 19, R255-79	5.7	84
23	Ovarian cancer: prevention, detection, and treatment of the disease and its recurrence. Molecular mechanisms and personalized medicine meeting report. *International Journal of Gynecological Cancer*, **2012**, 22, S45-57	3.5	33
22	Common variants at 19p13 are associated with susceptibility to ovarian cancer. *Nature Genetics*, **2010**, 42, 880-4	36.3	210
21	Menstrual and reproductive factors in relation to mammographic density: the Study of Women's Health Across the Nation (SWAN). *Breast Cancer Research and Treatment*, **2008**, 112, 165-74	4.4	54
20	Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. *Cancer Research*, **2007**, 67, 3027-35	10.1	75
19	Gender of offspring and maternal ovarian cancer risk. *Gynecologic Oncology*, **2006**, 101, 476-80	4.9	9
18	Anthropometry and the risk of epithelial ovarian cancer. *Cancer*, **2006**, 106, 2247-57	6.4	32
17	Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer. *International Journal of Cancer*, **2006**, 118, 1292-301	7.5	33

16	Breast cancer risk factors and mammographic breast density in women over age 70. *Breast Cancer Research and Treatment*, **2006**, 97, 157-66	4.4	30
15	Association of estrogen receptor alpha polymorphisms with breast cancer risk in older Caucasian women. *International Journal of Cancer*, **2005**, 116, 984-91	7.5	25
14	Estrogen metabolizing polymorphisms and breast cancer risk among older white women. *Breast Cancer Research and Treatment*, **2005**, 93, 261-70	4.4	21
13	Inflammation and endometrial cancer: a hypothesis. *Cancer Epidemiology Biomarkers and Prevention* , **2005**, 14, 2840-7	4	172
12	Short-term oral contraceptive use and the risk of epithelial ovarian cancer. *American Journal of Epidemiology*, **2005**, 162, 66-72	3.8	19
11	Ovarian cancer and polymorphisms in the androgen and progesterone receptor genes: a HuGE review. *American Journal of Epidemiology*, **2004**, 159, 319-35	3.8	46
10	Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. *American Journal of Obstetrics and Gynecology*, **2004**, 191, 733-40	6.4	156
9	Alcohol Consumption and the Risk of Mucinous and Nonmucinous Epithelial Ovarian Cancer. *Obstetrics and Gynecology*, **2003**, 102, 1336-1343	4.9	19
8	Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States). *Cancer Causes and Control*, **2003**, 14, 439-46	2.8	12
7	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. *Breast Cancer Research and Treatment*, **2003**, 82, 191-7	4.4	56
6	Ovarian cancer and high-risk women-implications for prevention, screening, and early detection. *Gynecologic Oncology*, **2003**, 91, 15-31	4.9	52
5	Alcohol consumption and the risk of mucinous and nonmucinous epithelial ovarian cancer. *Obstetrics and Gynecology*, **2003**, 102, 1336-43	4.9	22
4	Effect of raloxifene on sexual function in older postmenopausal women with osteoporosis. *Obstetrics and Gynecology*, **2003**, 101, 353-61	4.9	12
3	Cigarette smoking and the risk of mucinous and nonmucinous epithelial ovarian cancer. *Epidemiology*, **2002**, 13, 467-71	3.1	53
2	Reproductive risk factors for epithelial ovarian cancer according to histologic type and invasiveness. *Annals of Epidemiology*, **2001**, 11, 568-74	6.4	98
1	Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk		1